Celgene Corp. Sets New 1-Year High at $174.66 (CELG)
Celgene Corp. (NASDAQ:CELG) set a new 52-week high during trading hours on Monday, AnalystRatings.NET reports. The company traded as high as $174.66 and last traded at $163.83, with a volume of 6,461,932 shares. The stock had previously closed at $169.81.
Several analysts have recently commented on the stock. Analysts at Barclays raised their price target on shares of Celgene Corp. from $173.00 to $182.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Nomura initiated coverage on shares of Celgene Corp. in a research note to investors on Wednesday, January 8th. They set a “buy” rating on the stock. Finally, analysts at UBS AG downgraded shares of Celgene Corp. from a “hold” rating to a “sell” rating in a research note to investors on Tuesday, January 7th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-two have issued a buy rating to the company. Celgene Corp. currently has a consensus rating of “Buy” and an average price target of $163.44.
Celgene Corp. has a one year low of $95.37 and a one year high of $173.80. The stock’s 50-day moving average is $165.7 and its 200-day moving average is $149.2. The company has a market cap of $67.876 billion and a P/E ratio of 48.89.
Celgene Corp. (NASDAQ:CELG) last released its earnings data on Thursday, October 24th. The company reported $1.56 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the company posted $1.29 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Analysts expect that Celgene Corp. will post $6.00 EPS for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.